Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7
Author
Abstract
Suggested Citation
DOI: 10.2165/11587150-000000000-00000
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Frank R. Lichtenberg, 2014.
"Has Medical Innovation Reduced Cancer Mortality?,"
CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
- Frank R. Lichtenberg, 2010. "Has medical innovation reduced cancer mortality?," NBER Working Papers 15880, National Bureau of Economic Research, Inc.
- Robert M. Solow, 1956. "A Contribution to the Theory of Economic Growth," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 70(1), pages 65-94.
- Plutarchos Sakellaris & Daniel J. Wilson, 2004.
"Quantifying Embodied Technological Change,"
Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 7(1), pages 1-26, January.
- Plutarchos Sakellaris & Daniel J. Wilson, 2001. "Quantifying embodied technological change," Working Paper Series 2001-16, Federal Reserve Bank of San Francisco.
- Sakellaris, Plutarchos & Wilson, Daniel J., 2002. "Quantifying embodied technological change," Working Paper Series 158, European Central Bank.
- Mark Bils, 2004. "Measuring the Growth from Better and Better Goods," NBER Working Papers 10606, National Bureau of Economic Research, Inc.
- Hercowitz, Zvi, 1998. "The 'embodiment' controversy: A review essay," Journal of Monetary Economics, Elsevier, vol. 41(1), pages 217-224, February.
- Christopher J. Ruhm, 2006.
"Macroeconomic Conditions, Health and Mortality,"
Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, chapter 1,
Edward Elgar Publishing.
- Christopher J. Ruhm, 2004. "Macroeconomic Conditions, Health and Mortality," NBER Working Papers 11007, National Bureau of Economic Research, Inc.
- Frank Lichtenberg, 2011.
"The quality of medical care, behavioral risk factors, and longevity growth,"
International Journal of Health Economics and Management, Springer, vol. 11(1), pages 1-34, March.
- Frank R. Lichtenberg, 2009. "The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth," NBER Working Papers 15068, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2009.
"Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003,"
Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 519-534, May.
- Frank R. Lichtenberg, 2008. "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," NBER Working Papers 14008, National Bureau of Economic Research, Inc.
- Kevin M. Murphy & Robert H. Topel, 2006.
"The Value of Health and Longevity,"
Journal of Political Economy, University of Chicago Press, vol. 114(5), pages 871-904, October.
- Kevin M. Murphy & Robert H. Topel, 2005. "The Value of Health and Longevity," NBER Working Papers 11405, National Bureau of Economic Research, Inc.
- Charles R. Hulten, 1992. "Growth Accounting When Technical Change is Embodied in Capital," NBER Working Papers 3971, National Bureau of Economic Research, Inc.
- Stefan Hupfeld, 2011. "Non-monotonicity in the longevity–income relationship," Journal of Population Economics, Springer;European Society for Population Economics, vol. 24(1), pages 191-211, January.
- Timothy F. Bresnahan & Robert J. Gordon, 1996. "The Economics of New Goods," NBER Books, National Bureau of Economic Research, Inc, number bres96-1.
- Romer, Paul M, 1990.
"Endogenous Technological Change,"
Journal of Political Economy, University of Chicago Press, vol. 98(5), pages 71-102, October.
- Paul Romer, 1989. "Endogenous Technological Change," NBER Working Papers 3210, National Bureau of Economic Research, Inc.
- Paul M Romer, 1999. "Endogenous Technological Change," Levine's Working Paper Archive 2135, David K. Levine.
- Gene M. Grossman & Elhanan Helpman, 1993. "Innovation and Growth in the Global Economy," MIT Press Books, The MIT Press, edition 1, volume 1, number 0262570971, December.
- Hulten, Charles R, 1992. "Growth Accounting When Technical Change Is Embodied in Capital," American Economic Review, American Economic Association, vol. 82(4), pages 964-980, September.
- Bahk, Byong-Hong & Gort, Michael, 1993. "Decomposing Learning by Doing in New Plants," Journal of Political Economy, University of Chicago Press, vol. 101(4), pages 561-583, August.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Kyle, Margaret & Dubois, Pierre, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality," CEPR Discussion Papers 11487, C.E.P.R. Discussion Papers.
- Frank R. Lichtenberg & Billie Pettersson, 2014.
"The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 23(3), pages 239-273, April.
- Frank Lichtenberg & Billie Pettersson, 2012. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data," CESifo Working Paper Series 3894, CESifo.
- Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
- Frank R. Lichtenberg, 2015.
"Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010,"
International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 277-299, July.
- Frank Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series 5166, CESifo.
- Lichtenberg Frank R., 2013.
"The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files,"
Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 1-33, January.
- Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files," NBER Working Papers 18552, National Bureau of Economic Research, Inc.
- Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2024.
"Financial incentives and prescribing behavior in primary care,"
Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 696-713, April.
- Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2021. "Financial incentives and prescribing behaviour in primary care," Working Papers 181cherp, Centre for Health Economics, University of York.
- Lichtenberg, Frank R., 2013.
"The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007,"
Social Science & Medicine, Elsevier, vol. 77(C), pages 50-59.
- Frank R. Lichtenberg, 2011. "The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007," NBER Working Papers 17414, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Kyle, Margaret, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality Rates," TSE Working Papers 16-688, Toulouse School of Economics (TSE).
- Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
- Nishimura, Junichi & Nagaoka, Sadao & Yoneyama-Hirozane, Mariko, 2022. "The impact of science-intensive drugs on longevity and cure rate: Evidence from new prescription drugs launched in Japan," Journal of the Japanese and International Economies, Elsevier, vol. 64(C).
- Panagiotis Petrou, 2019. "Seeking to introduce a pharmacoeconomics framework in Cyprus," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(3), pages 309-310, April.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Frank Lichtenberg, 2010. "The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France," CESifo Working Paper Series 3095, CESifo.
- Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
- Frank Lichtenberg, 2011.
"The quality of medical care, behavioral risk factors, and longevity growth,"
International Journal of Health Economics and Management, Springer, vol. 11(1), pages 1-34, March.
- Frank R. Lichtenberg, 2009. "The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth," NBER Working Papers 15068, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg & Gautier Duflos, 2008.
"Pharmaceutical innovation and the longevity of Australians: A first look,"
Advances in Health Economics and Health Services Research, in: Beyond Health Insurance: Public Policy to Improve Health, pages 95-117,
Emerald Group Publishing Limited.
- Frank R. Lichtenberg & Gautier Duflos, 2008. "Pharmaceutical innovation and the longevity of Australians: a first look," NBER Working Papers 14009, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2012. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," NBER Working Papers 18235, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg & Suchin Virabhak, 2007.
"Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health',"
Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 371-392.
- Frank R. Lichtenberg & Suchin Virabhak, 2002. "Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"," NBER Working Papers 9351, National Bureau of Economic Research, Inc.
- Jeremy Greenwood & Boyan Jovanovic, 2001.
"Accounting for Growth,"
NBER Chapters, in: New Developments in Productivity Analysis, pages 179-224,
National Bureau of Economic Research, Inc.
- Jeremy Greenwood & Boyan Jovanovic, 1998. "Accounting for Growth," NBER Working Papers 6647, National Bureau of Economic Research, Inc.
- Jeremy Greenwood & Boyan Jovanovic, 2000. "Accounting for Growth," RCER Working Papers 475, University of Rochester - Center for Economic Research (RCER).
- Frank R. Lichtenberg, 2015.
"Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010,"
International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 277-299, July.
- Frank Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series 5166, CESifo.
- Daniel J. Wilson, 2002.
"Is Embodied Technology the Result of Upstream R&D? Industry-Level Evidence,"
Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 5(2), pages 285-317, April.
- Daniel J. Wilson, 2001. "Is embodied technology the result of upstream R&D? industry-level evidence," Working Paper Series 2001-17, Federal Reserve Bank of San Francisco.
- Frank R. Lichtenberg, 2005. "Pharmaceutical Knowledge-Capital Accumulation and Longevity," NBER Chapters, in: Measuring Capital in the New Economy, pages 237-274, National Bureau of Economic Research, Inc.
- Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
- Plutarchos Sakellaris & Daniel J. Wilson, 2004.
"Quantifying Embodied Technological Change,"
Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 7(1), pages 1-26, January.
- Plutarchos Sakellaris & Daniel J. Wilson, 2001. "Quantifying embodied technological change," Working Paper Series 2001-16, Federal Reserve Bank of San Francisco.
- Sakellaris, Plutarchos & Wilson, Daniel J., 2002. "Quantifying embodied technological change," Working Paper Series 158, European Central Bank.
- Frank R. LICHTENBERG, 2018.
"The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries,"
JODE - Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Lichtenberg, Frank R., 2018. "The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries," Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," NBER Working Papers 24536, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers id:12757, eSocialSciences.
- Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
- Charles R. Hulten & Leonard I. Nakamura, 2017.
"Accounting for Growth in the Age of the Internet The Importance of Output-Saving Technical Change,"
Working Papers
17-24, Federal Reserve Bank of Philadelphia.
- Charles Hulten & Leonard Nakamura, 2017. "Accounting for Growth in the Age of the Internet: The Importance of Output-Saving Technical Change," NBER Working Papers 23315, National Bureau of Economic Research, Inc.
- Lichtenberg Frank R., 2018.
"The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis,"
Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
- Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
- Roberto M. Samaniego & Juliana Yu Sun, 2022.
"The Embodiment Controversy: On the Policy Implications of Vintage Capital Models,"
Journal of Money, Credit and Banking, Blackwell Publishing, vol. 54(5), pages 1175-1222, August.
- Samaniego, Roberto, 2016. "The Embodiment Controversy: on the Policy Implications of Vintage Capital models," MPRA Paper 73348, University Library of Munich, Germany.
- Jason G. Cummins & Giovanni L. Violante, 2002.
"Investment-Specific Technical Change in the US (1947-2000): Measurement and Macroeconomic Consequences,"
Review of Economic Dynamics, Elsevier for the Society for Economic Dynamics, vol. 5(2), pages 243-284, April.
- Violante, Giovanni & Cummins, Jason G, 2002. "Investment-Specific Technical Change in the US (1947-2000): Measurement and Macroeconomic Consequences," CEPR Discussion Papers 3584, C.E.P.R. Discussion Papers.
- Jason G. Cummins & Giovanni L. Violante, 2002. "Investment-specific technical change in the US (1947-2000): measurement and macroeconomics consequences," Finance and Economics Discussion Series 2002-10, Board of Governors of the Federal Reserve System (U.S.).
- Charles R. Hulten, 1996. "Quality Change in Capital Goods and Its Impact on Economic Growth," NBER Working Papers 5569, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2022. "The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 158(1), pages 1-24, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:30:y:2012:i:3:p:197-211. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.